

**Listing of Claims**

1. (Currently amended) A sustained release tamsulosin formulation, comprising 0.03% to 3% by weight tamsulosin or a pharmaceutically acceptable salt thereof, a hydrophobic polymer present at about 10% to 65% w/w of the formulation, a microsphere formulating agent present at about 20% to 65% w/w of the formulation, and a diluent present at about 10% to 40% w/w of the formulation.
2. (Original) The sustained release tamsulosin formulation as claimed in claim 1, wherein the diluent is selected from the group consisting of lactose, starch, mannitol, sodium hydroxylpropyl cellulose, sodium starch, microcrystalline cellulose, glyceryl behenate, talcum powder, stearic acid, stearate and sodium stearyl fumarate.
3. (Original) The sustained release tamsulosin formulation as claimed in claim 1, wherein the hydrophobic polymer is selected from a group of pH-dependent polymers and pH-independent polymers.
4. (Original) The sustained release tamsulosin formulation as claimed in claim 3, wherein the hydrophobic polymer is selected from the group consisting of sodium carboxymethyl cellulose, cellulose acetate, ethyl cellulose (EC), hydroxypropyl methyl-cellulose acetate succinate (HPMCAS) and cellulose acetate phthalate (CAP).

Applicant: Ching-Fen Hsiao et al.  
Serial No.: 10/784,499  
Filed: February 23, 2004  
Page: 3

5. (Original) The sustained release tamsulosin formulation as claimed in claim 1, wherein the microsphere forming agent is selected from the group consisting of glyceryl triacetate, glyceryl monostearate, glyceryl behenate, paraffin wax and carnauba wax.